211 related articles for article (PubMed ID: 34546005)
1. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
Erku D; Schneider J; Scuffham P
Pharmacol Res Perspect; 2021 Oct; 9(5):e00862. PubMed ID: 34546005
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
Zuidema S; Desar IME; van Erp NP; Kievit W
Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
Fahmy A; Hopkins AM; Sorich MJ; Rowland A
Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
[No Abstract] [Full Text] [Related]
5. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
Freeman K; Connock M; Cummins E; Gurung T; Taylor-Phillips S; Court R; Saunders M; Clarke A; Sutcliffe P
Health Technol Assess; 2015 Nov; 19(91):1-321, v-vi. PubMed ID: 26542268
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring in cancer chemotherapy.
Bach DM; Straseski JA; Clarke W
Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
[TBL] [Abstract][Full Text] [Related]
7. On precision dosing of oral small molecule drugs in oncology.
Lyashchenko AK; Cremers S
Br J Clin Pharmacol; 2021 Feb; 87(2):263-270. PubMed ID: 32621551
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments.
Vithanachchi DT; Maujean A; Downes MJ; Scuffham P
Br J Clin Pharmacol; 2021 Feb; 87(2):271-283. PubMed ID: 32692416
[TBL] [Abstract][Full Text] [Related]
9. The past, present, and future of chemotherapy with a focus on individualization of drug dosing.
DeRidder L; Rubinson DA; Langer R; Traverso G
J Control Release; 2022 Dec; 352():840-860. PubMed ID: 36334860
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
11. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N
Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
[TBL] [Abstract][Full Text] [Related]
13. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.
Conti RM; Padula WV; Becker RV; Salamone S
J Manag Care Spec Pharm; 2021 Aug; 27(8):1077-1085. PubMed ID: 34337991
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of therapeutic drug monitoring: a systematic review.
Touw DJ; Neef C; Thomson AH; Vinks AA;
Ther Drug Monit; 2005 Feb; 27(1):10-7. PubMed ID: 15665740
[TBL] [Abstract][Full Text] [Related]
18. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
19. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
Verheijen RB; Yu H; Schellens JHM; Beijnen JH; Steeghs N; Huitema ADR
Clin Pharmacol Ther; 2017 Nov; 102(5):765-776. PubMed ID: 28699160
[TBL] [Abstract][Full Text] [Related]
20. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology.
Menz BD; Stocker SL; Verougstraete N; Kocic D; Galettis P; Stove CP; Reuter SE
Br J Clin Pharmacol; 2021 Feb; 87(2):227-236. PubMed ID: 32430968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
